Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480789 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EHSD17B10POLBKMT2A | |
| SCHEMBL21729771 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EHSD17B10POLBKMT2A | |
| SCHEMBL25237379 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10POLBKMT2A | |
| SCHEMBL21717728 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10POLBKMT2A | |
| SCHEMBL21730581 | 0.79 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10POLBKMT2A | |
| SCHEMBL14478276 | 0.79 | — | — | |
| SCHEMBL2022682 | 0.79 | — | — | |
| SCHEMBL13692285 | 0.79 | — | — | |
| SCHEMBL19185911 | 0.78 | ALDH1A1 (0.45) | ALDH1A1KDM4EHSD17B10POLBKMT2A | |
| SCHEMBL11469262 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772312-A | Epoxy resin material and preparation method thereof | 株洲时代新材料科技股份有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-115772312-A | Epoxy resin material and preparation method thereof | 株洲时代新材料科技股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| WO-2010088450-A2 | METHODS FOR TREATING DISEASES ASSOCIATED WITH THE MODULATION OF SERCA | CELLADON CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088450-A2 | METHODS FOR TREATING DISEASES ASSOCIATED WITH THE MODULATION OF SERCA | CELLADON CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-1987037-A2 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | ALDH1A1 3643/4885KDM4E 3110/4885HSD17B10 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.